Translational Research

Description

The spectrum ranges from the development of biomarkers for the monitoring of new therapeutics to proof-of-concept trials and investigator-initiated trials (phase I / II) to test innovative immunotherapeutic approaches that are based on new pathogenetic findings. In addition to close networking with the other research groups within the institute, there is intensive cooperation with the clinical partners, in particular with the interdisciplinary clinical research groups located at the institute (nephrology / transplantation medicine, intensive care medicine, dermatology) as well as with biotech companies, clinical research organizations (CRO Charité, Parexel) and the pharmaceutical industry (Bayer-Schering Pharma, Biogen, Novartis, Nycomed, Roche, Johnson / Johnson, etc.). (Description adapted from working group website: see link above)